Anti-Mouse/Rat CD90.1 (Thy-1.1) (Clone OX-7) – PE

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Clone OX-7 activity is directed against both rat and murine CD90/Thy-1.

CD90 is present on a variety of cell types in murine and rat, including lymphatic vessels¹, T cells², neurons³ and fibroblasts⁴.

CD90/Thy-1 (murine CD90.1/Thy-1.1) is a cell surface glycoprotein that was the first protein of the immunoglobulin superfamily to be discovered⁵. The 25 kDa core protein is N-glycosylated at three sites, leading to isoforms with a range of molecular masses (25-37 kDa). CD90 is composed of a single V-like immunoglobulin domain anchored by a disulfide bond between Cys 28 and Cys 104. Despite its lack of an intracellular domain, CD90 is located in the outer leaflet of lipid rafts at the cell membrane, allowing signaling functions by cis- and trans-interactions with a variety of proteins, including G inhibitory proteins, the Src family kinase (SFK) members src and c-fyn, and tubulin.

CD90 has been found to play a role in numerous cellular activities, such as cell adhesion, apoptosis, metastasis, inflammation, and fibrosis. In mouse strains expressing CD90.1, it is expressed on early-stage hematopoietic cells in bone marrow, thymocytes, and circulating mature T cells. The OX-7 antibody has been reported to induce leukocyte activation, glomerular nephritis, apoptosis in glomerular mesangial cells, and vascular permeability. CD90 can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Diseases associated with CD90 dysfunction include nasopharyngeal carcinoma and thymoma.

1. Jurisic G, Iolyeva M, Proulx ST, et. al. Exp Cell Res. 316: 2982–2992. 2010.
2. Ledbetter JA, Rouse RV, Micklem HS, et. al. J Exp Med. 152: 280–295. 1980.
3. Schrader JW, Battye F, Scollay R. Proc Natl Acad Sci. U S A 79: 4161–4165. 1982.
4. Phipps RP, Baecher C, Frelinger JG, et. al. Eur J Immunol. 20: 1723–1727. 1990.
5. Hu P, Leyton L, Hagood JS, Barker TH. Front Cell Dev Biol. Jun 6;10:928510. 2022.
6. Crook K, Hunt SV. Dev Immunol. 4(4):235-46. 1996.
7. Zhang J, Wang JH. Methods Mol Biol. 1842:217-228. 2018
8. Hermans MH, Opstelten D. J Histochem Cytochem. Dec;39(12):1627-34. 1991